330 related articles for article (PubMed ID: 31361367)
1. Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Singleton A; Shaw LM; Trojanowski JQ; Frasier M; Simuni T; Iranzo A; Oertel W; Siderowf A; Weintraub D; Seibyl J; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Marek K; Galasko D;
Mov Disord; 2019 Sep; 34(9):1354-1364. PubMed ID: 31361367
[TBL] [Abstract][Full Text] [Related]
2. Accurate Detection of α-Synuclein Seeds in Cerebrospinal Fluid from Isolated Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the DeNovo Parkinson (DeNoPa) Cohort.
Concha-Marambio L; Weber S; Farris CM; Dakna M; Lang E; Wicke T; Ma Y; Starke M; Ebentheuer J; Sixel-Döring F; Muntean ML; Schade S; Trenkwalder C; Soto C; Mollenhauer B
Mov Disord; 2023 Apr; 38(4):567-578. PubMed ID: 36781413
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
[TBL] [Abstract][Full Text] [Related]
5. Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease.
Yan S; Jiang C; Janzen A; Barber TR; Seger A; Sommerauer M; Davis JJ; Marek K; Hu MT; Oertel WH; Tofaris GK
JAMA Neurol; 2024 Jan; 81(1):59-68. PubMed ID: 38048087
[TBL] [Abstract][Full Text] [Related]
6. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.
van Dijk KD; Bidinosti M; Weiss A; Raijmakers P; Berendse HW; van de Berg WD
Eur J Neurol; 2014 Mar; 21(3):388-94. PubMed ID: 23631635
[TBL] [Abstract][Full Text] [Related]
7. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
8. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
Majbour NK; Vaikath NN; Eusebi P; Chiasserini D; Ardah M; Varghese S; Haque ME; Tokuda T; Auinger P; Calabresi P; Parnetti L; El-Agnaf OM
Mov Disord; 2016 Oct; 31(10):1535-1542. PubMed ID: 27548849
[TBL] [Abstract][Full Text] [Related]
10. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
[TBL] [Abstract][Full Text] [Related]
11. Predictors of the Rapid Progression in Prodromal Parkinson's Disease: A Longitudinal Follow-Up Study.
Liu P; Chen L; He X; Mao L
Gerontology; 2024; 70(6):595-602. PubMed ID: 38565088
[TBL] [Abstract][Full Text] [Related]
12. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
13. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
14. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
[TBL] [Abstract][Full Text] [Related]
15. Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
Noyce AJ; Dickson J; Rees RN; Bestwick JP; Isaias IU; Politis M; Giovannoni G; Warner TT; Lees AJ; Schrag A
Mov Disord; 2018 Mar; 33(3):478-482. PubMed ID: 29380907
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Shaw LM; Trojanowski JQ; Singleton A; Frasier M; Marek K; Galasko D;
Neurology; 2017 Nov; 89(19):1959-1969. PubMed ID: 29030452
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.
Kang UJ; Boehme AK; Fairfoul G; Shahnawaz M; Ma TC; Hutten SJ; Green A; Soto C
Mov Disord; 2019 Apr; 34(4):536-544. PubMed ID: 30840785
[TBL] [Abstract][Full Text] [Related]
19. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
[TBL] [Abstract][Full Text] [Related]
20. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
